$PLSM

Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring

Pulsenmore (NASDAQ: PLSM, TASE: PLSM) announced its home ultrasound technology will be integrated at Lis Maternity and Women's Hospital at Ichilov in Israel, expanding access to at-home pregnancy monitoring. This move broadens the company's presence in central Israel and supports its hybrid monitoring model, combining hospital and at-home care. Pulsenmore's technology aims to improve maternal health by enabling remote ultrasound scans under medical guidance.

Original reporting
Published Aug 19, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring — source image
Decision brief

The 30-second read

$PLSMNeutralLow
01

Why it matters

The new hospital integration expands the company's service network but lacks disclosed financial magnitude, suggesting modest market impact.

02

Market read

Operational expansion with limited immediate trading relevance; may be a longer‑term growth catalyst.

03

What to watch

Potential regulatory approvals and reimbursement pathways in Israel could affect rollout speed.

Relevance 4/10Novelty 5/10Timing: today

Background

Pulsenmore develops home-use ultrasound devices that connect patients with clinicians remotely, aiming to improve prenatal care access.

Company-level read

Ticker impact

$PLSMNeutralMedium confidence
Context

Pulsenmore announced the integration of its home ultrasound technology at Ichilov's Lis Maternity Hospital, expanding its Israeli footprint.

Expected impact

Limited short-term price movement; potential modest upside if rollout accelerates revenue growth.

Evidence & confidence

No disclosed revenue impact or funding; the news is primarily operational expansion.

Market effects

Highlights growing interest in at‑home diagnostic devices within the med‑tech sector.

May encourage Israeli hospitals to consider similar tele‑ultrasound solutions.

Limited; primarily relevant to niche maternal‑health technology investors.

Counterpoint

The expansion may strain Pulsenmore's resources without delivering immediate revenue, risking dilution of focus.

Key entities

  • Pulsenmore Ltd.

    Developer of home ultrasound solutions.

  • Lis Maternity and Women's Hospital (Ichilov)

    Major Israeli maternity hospital adopting the technology.

Related articles

$PLSMMed

Pulsenmore Ltd.: Pulsenmore Expands Its Fertility Platform into the UK

Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM) has registered its home ultrasound system, Pulsenmore FC, with the UK's MHRA, allowing it to market the product in the UK and Northern Ireland. The system is designed for women undergoing IVF and fertility preservation treatments, enabling at-home monitoring. The UK fertility market saw over 100,000 treatment cycles in 2024, according to the HFEA. This expansion follows the company's recent European registration under the Medical Device Regulation (MDR

$PLSMMed

Pulsenmore Expands Its Fertility Platform into the UK

Pulsenmore (NASDAQ: PLSM, TASE: PLSM) has expanded its fertility platform into the UK after completing MHRA registration for its home ultrasound system, Pulsenmore FC. The system allows women undergoing IVF to perform vaginal ultrasound scans at home, reducing clinic visits. The UK market saw over 100,000 fertility treatment cycles in 2024, according to the HFEA.

$PLSMMed

Pulsenmore Ltd. (PLSM): Financial results for H1 2026

Pulsenmore Ltd. (PLSM) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 Management to Host Webcast today at 8:30 am ET to discuss Results and Provide Business Update Omer, Israel –August 31, 2026 – Pulsenmore Ltd. (Nasdaq/TASE: PLSM ), a leadin

$PLSMMed

Pulsenmore stock surges 160% on Israel AI program selection By Investing.com

Pulsenmore Ltd. (NASDAQ:PLSM) shares jumped about 160% after the company said it was selected for Israel’s Healthcare AI Regulatory Sandbox Program by the Israel Innovation Authority and Ministry of Health. Pulsenmore will receive funding for a $1 million project to develop and clinically validate AI for its home ultrasound platform, with Beilinson Hospital/Clalit Health Services.

$BMEAMedAI 8/10

Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Biomea Fusion (BMEA) reported that BMF-650, its GLP-1 drug, showed up to 6.1% weight loss in early trials. The company cautioned about interpreting results due to placebo effects. BMF-650 was generally well-tolerated, with mild to moderate side effects. Biomea plans further studies and seeks partnerships for Phase II development, focusing on obesity and diabetes.

$NVDAMed

NVIDIA Halts RTX 5090 GPU Production?

NVIDIA may have halted production of its RTX 5090 GPU, according to hardware leakers. The card, launched at $1999, now sells for $4,000-$5,000 due to memory price increases. Reports suggest AI data centers are buying the consumer version instead of the more expensive RTX Pro GPUs, prompting the halt. NVIDIA faces no direct competition from AMD in this segment.